Catalyst

Slingshot members are tracking this event:

Janssen (JNJ) Submits Biologics License Application (BLA) to the FDA for Guselkumab in Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
JNJ

100%
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 17, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Biologics License Application, Bla, Fda, Guselkumab, Adults, Moderate-to-severe, Plaque Psoriasis